13 Aug 2021 13:23
GENERAL TEXT AMENDMENT
The following amendment has been made to the Holding(s) in Company announcement released on 10th August at 9.53am under RNS No 1441I.
The shareholding percentage (but not the total shares) has been updated to reflect the pre-Warrant Share Admission number of ordinary shares outstanding as of August 5.
All other details remain unchanged.
The full amended text is shown below.
TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
GB00BKLTQ412
Issuer Name
AMRYT PHARMA PLC
UK or Non-UK Issuer
Non-UK
2. Reason for Notification
An event changing the breakdown of voting
3. Details of person subject to the notification obligation
Name
Athyrium Funds GP Holdings LLC
City of registered office (if applicable)
New York
Country of registered office (if applicable)
United States
4. Details of the shareholder
Name | City of registered office | Country of registered office |
Athyrium Opportunities III Acquisition 2 LP | Wilmington | United States |
Athyrium Opportunities II Acquisition 2 LP | Wilmington | United States |
5. Date on which the threshold was crossed or reached
05-Aug-2021
6. Date on which Issuer notified
09-Aug-2021
7. Total positions of person(s) subject to the notification obligation
| % of voting rights attached to shares (total of 8.A) | % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) | Total of both in % (8.A + 8.B) | Total number of voting rights held in issuer |
Resulting situation on the date on which threshold was crossed or reached | 14.420000 | 0.000000 | 14.420000 | 44286346 |
Position of previous notification (if applicable) |
|
|
|
|
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares
Class/Type of shares ISIN code(if possible) | Number of direct voting rights (DTR5.1) | Number of indirect voting rights (DTR5.2.1) | % of direct voting rights (DTR5.1) | % of indirect voting rights (DTR5.2.1) |
GB00BKLTQ412 | 0 | 44286346 | 0.000000 | 14.420000 |
Sub Total 8.A | 44286346 | 14.420000% | ||
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
Type of financial instrument | Expiration date | Exercise/conversion period | Number of voting rights that may be acquired if the instrument is exercised/converted | % of voting rights |
|
|
|
|
|
Sub Total 8.B1 |
|
|
| |
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
Type of financial instrument | Expiration date | Exercise/conversion period | Physical or cash settlement | Number of voting rights | % of voting rights |
|
|
|
|
|
|
Sub Total 8.B2 |
|
|
| ||
9. Information in relation to the person subject to the notification obligation
2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)
Ultimate controlling person | Name of controlled undertaking | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold |
Jeffrey Ferrell | Athyrium Funds GP Holdings LLC | 14.420000 | 0.000000 | 14.420000 |
Jeffrey Ferrell | Athyrium GP Holdings LLC | 8.530000 | 0.000000 | 8.530000 |
Jeffrey Ferrell | Athyrium Opportunities Associates II LP | 8.530000 | 0.000000 | 8.530000 |
Jeffrey Ferrell | Athyrium Opportunities II Acquisition 2 LP | 8.530000 | 0.000000 | 8.530000 |
Jeffrey Ferrell | Athyrium Opportunities Associates III GP LLC | 5.890000 | 0.000000 | 5.890000 |
Jeffrey Ferrell | Athyrium Opportunities Associates III LP | 5.890000 | 0.000000 | 5.890000 |
Jeffrey Ferrell | Athyrium Opportunities III Acquisition 2 LP | 5.890000 | 0.000000 | 5.890000 |
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
There are two chains of controlled undertakings, each controlled by Athyrium Funds GP Holdings LLC and, ultimately, Jeffrey Ferrell. As this was the first TR-1 report made through the ESS, there was a delay caused by registration. However, the Microsoft Word form of the notice was provided to the Issuer and the FCA email address on 09/08/2021.
12. Date of Completion
12-Aug-2021
13. Place Of Completion
New York, USA